Search Results

Filter
  • 1-10 of  10,775 results for ""Trifluridine""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib.

  • Authors : Hsiao KY; Artificial Intelligence Development Center, Fu Jen Catholic University, New Taipei City, Taiwan.; Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City, Taiwan.

Subjects: Pyridines*/Pyridines*/Pyridines*/therapeutic use ; Pyridines*/Pyridines*/Pyridines*/pharmacology ; Trifluridine*/Trifluridine*/Trifluridine*/therapeutic use

  • Source: The oncologist [Oncologist] 2024 Dec 06; Vol. 29 (12), pp. e1669-e1679.Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer.

  • Authors : Huang LZ; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.; Chen YQ

Subjects: Bevacizumab*/Bevacizumab*/Bevacizumab*/economics ; Bevacizumab*/Bevacizumab*/Bevacizumab*/therapeutic use ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy

  • Source: Frontiers in public health [Front Public Health] 2024 Nov 13; Vol. 12, pp. 1465898. Date of Electronic Publication: 2024 Nov 13 (Print Publication: 2024).Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancer.

  • Authors : Saito Y; Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-jo 15-chome, Teine-ku, Sapporo, 006-8585, Japan. .; Takekuma Y

Subjects: Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/pathology ; Neutropenia*/Neutropenia*/Neutropenia*/chemically induced

  • Source: Scientific reports [Sci Rep] 2024 Nov 06; Vol. 14 (1), pp. 26990. Date of Electronic Publication: 2024 Nov 06.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Cachexia and efficiency of trifluridine/thymidine phosphorylase inhibitor + bevacizumab in metastatic colorectal cancer.

  • Authors : Shibutani M; Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi Abeno-ku, Osaka City, 545-8585, Osaka Prefecture, Japan. .; Tanda H

Subjects: Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/pathology ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/complications

  • Source: Scientific reports [Sci Rep] 2024 Oct 29; Vol. 14 (1), pp. 25884. Date of Electronic Publication: 2024 Oct 29.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study.

  • Authors : Li B; Department of Medical Oncology, Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing, 100122, China.; Yang W

Subjects: Bevacizumab*/Bevacizumab*/Bevacizumab*/administration & dosage ; Bevacizumab*/Bevacizumab*/Bevacizumab*/adverse effects ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy

  • Source: British journal of cancer [Br J Cancer] 2024 Dec; Vol. 131 (11), pp. 1775-1780. Date of Electronic Publication: 2024 Oct 24.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

Record details

×
Academic Journal

Cost-effectiveness analysis of trifluridine/tipiracil in the treatment of heavily pretreated metastatic gastric cancer from the perspective of Chinese healthcare system.

  • Authors : Ying T; School of Pharmacy, Anhui Medical University, Hefei, Anhui, China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, Anhui, China.

Subjects: Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/pathology ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/economics

  • Source: BMJ open [BMJ Open] 2024 Nov 07; Vol. 14 (11), pp. e080846. Date of Electronic Publication: 2024 Nov 07.Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing thymidine phosphorylase.

  • Authors : Malier M; Univ.Grenoble Alpes, Inserm U1209, CNRS UMR5309, Institute for Advanced Biosciences, Team Mechanobiology, Immunity and Cancer, 38000, Grenoble, France.; Laverriere MH

Subjects: Trifluridine*/Trifluridine*/Trifluridine*/pharmacology ; Thymidine Phosphorylase*/Thymidine Phosphorylase*/Thymidine Phosphorylase*/metabolism ; Thymidine Phosphorylase*/Thymidine Phosphorylase*/Thymidine Phosphorylase*/genetics

  • Source: Cancer letters [Cancer Lett] 2024 Dec 01; Vol. 606, pp. 217307. Date of Electronic Publication: 2024 Oct 23.Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Characterising and preventing the gut microbiota's inactivation of trifluridine, a colorectal cancer drug.

  • Authors : McCoubrey LE; UCL School of Pharmacy, 29-39 Brunswick Square, London, WC1N 1AX, United Kingdom.; Shen C

Subjects: Trifluridine*/Trifluridine*/Trifluridine*/pharmacology ; Gastrointestinal Microbiome*/Gastrointestinal Microbiome*/Gastrointestinal Microbiome*/drug effects ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy

  • Source: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2024 Dec 01; Vol. 203, pp. 106922. Date of Publisher: Elsevier Science B.V Country of Publication: Netherlands NLM ID: 9317982 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.

  • Authors : Zhang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District Panjiayuan Nanli No. 17, Beijing, 100021, China.; Yang W

Subjects: Thymine*/Thymine*/Thymine*/administration & dosage ; Trifluridine*/Trifluridine*/Trifluridine*/administration & dosage ; Trifluridine*/Trifluridine*/Trifluridine*/therapeutic use

  • Source: Investigational new drugs [Invest New Drugs] 2024 Aug; Vol. 42 (4), pp. 454-461. Date of Electronic Publication: 2024 Jul 11.Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.

  • Authors : Botsen D; Medical Oncology Department, Godinot Cancer Institute, 1 avenue General Koenig, Reims 51100, France.; Chabaud S

Subjects: Adenocarcinoma*/Adenocarcinoma*/Adenocarcinoma*/drug therapy ; Adenocarcinoma*/Adenocarcinoma*/Adenocarcinoma*/pathology ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use Adenocarcinoma Of EsophagusFolfox protocol

  • Source: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2024 Aug; Vol. 56 (8), pp.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 100958385 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  10,775 results for ""Trifluridine""